RISDIPLAM vs RITLECITINIB: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
RISDIPLAM vs RITLECITINIB: Safety Overview
| Metric | RISDIPLAM | RITLECITINIB |
|---|---|---|
| Total FAERS Reports | 3,619 | 1,441 |
| Deaths Reported | 336 | 1 |
| Death Rate | 9.3% | 0.1% |
| Hospitalizations | 719 | 47 |
| Average Patient Age | 21.8 yrs | 34.7 yrs |
| % Female Patients | 55.2% | 65.0% |
| FDA Approval Date | Aug 7, 2020 | Jun 23, 2023 |
| Manufacturer | Genentech, Inc. | U.S. Pharmaceuticals |
| Route | ORAL | ORAL |
| Marketing Status | Prescription | Prescription |